Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3423
Flu Vaccines Market Dynamics: Influenza is a contagious respiratory infection that causes cough, runny nose, severe illness. As per the World Health Organization, 2018, over 4 million people were diagnosed with severe illness whereas over 0.1 million influenza-related deaths were registered. Additionally, as per the report published by Center for Disease Control and Prevention in 2019, over 90 pediatric deaths were registered owing to flu. Furthermore, growing research and development activities along with current clinical trials for developing novel flu vaccines shall bolster the flu vaccines market growth. Moreover, rise in the number of healthcare centers in both developed and developing nations has boosted the proliferation of the market. Additionally, many key players are heavily investing in research and development activities for increasing their manufacturing capabilities and the product spectrum. These vendors are establishing new facilities for enhancing their production capabilities. The demand for flu vaccines has skyrocketed due to the current COVID-19 pandemic and many companies are initiating in producing vaccines for this virus. For example, Bharat Biotech has declared to collaborate with FluGen, a US-based biotech company and the University of Wisconsin Madison for experimenting with flu vaccines that have the potential of fighting off the SARS COV-2 virus. Many players have also reached the levels of advance clinical trials and government bodies are providing financial as well as infrastructural support to these companies. Flu Vaccines Market Segmentation: By Product Type • Trivalent Flu Vaccines • Quadrivalent Flu Vaccines By Dosage Form • Intramuscular Injection • Nasal Sprays • Intradermal Shot By Distribution Channel • Hospitals • Community Clinics • Public Health Agencies • Workplace Purchasing • Retail Pharmacy • Mail Order Pharmacy By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa The market is categorized into product type, dosage form, distribution channel and region. The product type segment is fragmented into trivalent vaccines and quadrivalent vaccines. The dosage form segment is classified into intradermal shots, intramuscular injection and nasal shots. The distribution channel segment is diversified into hospitals, community clinics, public health agencies, workplace purchasing, retail pharmacy and mail order pharmacy. The hospital segment is anticipated to hold the largest flu vaccines market share owing to a rise in the number of multispecialty hospitals and advancements in the hospital infrastructure. Regional Analysis: The North America region is expected to dominate the market and this can be credited to the rising awareness regarding the spread and prevention of flu, growing investments in the research and development of flu vaccines, favorable reimbursement policies and a strong presence of key market players in the region. The Europe region has experienced the growing prevalence of flu in the region which has boosted the market growth in the region. Competitive Landscape: The major market players associated are Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., CSL Ltd. (Seqirus), Zydus Cadila, Bharat Biotech, Panacea Biotech, Mylan, Sinovac Biotech,Mitsubishi Tanabe Pharma. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global flu vaccines market by product type, by dosage form, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Influenza is a contagious respiratory infection that causes cough, runny nose, severe illness. As per the World Health Organization, 2018, over 4 million people were diagnosed with severe illness whereas over 0.1 million influenza-related deaths were registered. Additionally, as per the report published by Center for Disease Control and Prevention in 2019, over 90 pediatric deaths were registered owing to flu. Furthermore, growing research and development activities along with current clinical trials for developing novel flu vaccines shall bolster the flu vaccines market growth.
Moreover, rise in the number of healthcare centers in both developed and developing nations has boosted the proliferation of the market. Additionally, many key players are heavily investing in research and development activities for increasing their manufacturing capabilities and the product spectrum. These vendors are establishing new facilities for enhancing their production capabilities. The demand for flu vaccines has skyrocketed due to the current COVID-19 pandemic and many companies are initiating in producing vaccines for this virus. For example, Bharat Biotech has declared to collaborate with FluGen, a US-based biotech company and the University of Wisconsin Madison for experimenting with flu vaccines that have the potential of fighting off the SARS COV-2 virus. Many players have also reached the levels of advance clinical trials and government bodies are providing financial as well as infrastructural support to these companies.
Flu Vaccines Market Segmentation:
By Product Type • Trivalent Flu Vaccines • Quadrivalent Flu Vaccines
By Dosage Form • Intramuscular Injection • Nasal Sprays • Intradermal Shot
By Distribution Channel • Hospitals • Community Clinics • Public Health Agencies • Workplace Purchasing • Retail Pharmacy • Mail Order Pharmacy
By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa
The market is categorized into product type, dosage form, distribution channel and region. The product type segment is fragmented into trivalent vaccines and quadrivalent vaccines. The dosage form segment is classified into intradermal shots, intramuscular injection and nasal shots. The distribution channel segment is diversified into hospitals, community clinics, public health agencies, workplace purchasing, retail pharmacy and mail order pharmacy. The hospital segment is anticipated to hold the largest flu vaccines market share owing to a rise in the number of multispecialty hospitals and advancements in the hospital infrastructure. Regional Analysis: The North America region is expected to dominate the market and this can be credited to the rising awareness regarding the spread and prevention of flu, growing investments in the research and development of flu vaccines, favorable reimbursement policies and a strong presence of key market players in the region. The Europe region has experienced the growing prevalence of flu in the region which has boosted the market growth in the region. Competitive Landscape: The major market players associated are Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., CSL Ltd. (Seqirus), Zydus Cadila, Bharat Biotech, Panacea Biotech, Mylan, Sinovac Biotech,Mitsubishi Tanabe Pharma. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global flu vaccines market by product type, by dosage form, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Flu Vaccines Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Flu Vaccines Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Flu Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Flu Vaccines Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Trivalent Vaccines 7.2. Quadrivalent Vaccines 8. Flu Vaccines Market, By Dosage Form Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Intramuscular Injection 8.2. Nasal Sprays 8.3. Intradermal Shots 9. Flu Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Community Clinics 9.3. Public Health Agencies 9.4. Workplace Purchasing 9.5. Retail Pharmacy 9.6. Mail Order Pharmacy 10. North America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Sanofi Pasteur Inc. (Sanofi S/A) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. AstraZeneca 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Abbott 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. GlaxoSmithKline Plc. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Serum Institute of India Pvt. Ltd. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. CSL Ltd. (Seqirus) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Zydus Cadila 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Bharat Biotech 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Panacea Biotech 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Mylan 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.Sinovac Biotech 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Mitsubishi Tanabe Pharma 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Flu Vaccines Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Flu Vaccines Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Flu Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Flu Vaccines Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Trivalent Vaccines 7.2. Quadrivalent Vaccines
8. Flu Vaccines Market, By Dosage Form Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Intramuscular Injection 8.2. Nasal Sprays 8.3. Intradermal Shots
9. Flu Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospitals 9.2. Community Clinics 9.3. Public Health Agencies 9.4. Workplace Purchasing 9.5. Retail Pharmacy 9.6. Mail Order Pharmacy
10. North America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Sanofi Pasteur Inc. (Sanofi S/A) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. AstraZeneca 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Abbott 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. GlaxoSmithKline Plc. 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Serum Institute of India Pvt. Ltd. 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. CSL Ltd. (Seqirus) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Zydus Cadila 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Bharat Biotech 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Panacea Biotech 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10.Mylan 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11.Sinovac Biotech 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12.Mitsubishi Tanabe Pharma 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics